These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 10887312

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
    Gafvelin G, Thunberg S, Kronqvist M, Grönlund H, Grönneberg R, Troye-Blomberg M, Akdis M, Fiebig H, Purohit A, Horak F, Reisinger J, Niederberger V, Akdis CA, Cromwell O, Pauli G, Valenta R, van Hage M.
    Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
    [Abstract] [Full Text] [Related]

  • 4. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population.
    Pauli G, Purohit A, Oster JP, De Blay F, Vrtala S, Niederberger V, Kraft D, Valenta R.
    Clin Exp Allergy; 2000 Aug; 30(8):1076-84. PubMed ID: 10931114
    [Abstract] [Full Text] [Related]

  • 5. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen.
    Hochreiter R, Stepanoska T, Ferreira F, Valenta R, Vrtala S, Thalhamer J, Hartl A.
    Eur J Immunol; 2003 Jun; 33(6):1667-76. PubMed ID: 12778485
    [Abstract] [Full Text] [Related]

  • 6. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1.
    Vrtala S, Hirtenlehner K, Susani M, Akdis M, Kussebi F, Akdis CA, Blaser K, Hufnagl P, Binder BR, Politou A, Pastore A, Vangelista L, Sperr WR, Semper H, Valent P, Ebner C, Kraft D, Valenta R.
    FASEB J; 2001 Sep; 15(11):2045-7. PubMed ID: 11511511
    [Abstract] [Full Text] [Related]

  • 7. Molecular composition and biological activity of commercial birch pollen allergen extracts.
    Focke M, Marth K, Valenta R.
    Eur J Clin Invest; 2009 May; 39(5):429-36. PubMed ID: 19302561
    [Abstract] [Full Text] [Related]

  • 8. Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy.
    Batard T, Didierlaurent A, Chabre H, Mothes N, Bussières L, Bohle B, Couret MN, Ball T, Lemoine P, Focks Tejkl M, Chenal A, Clément G, Dupont F, Valent P, Krauth MT, André C, Valenta R, Moingeon P.
    Int Arch Allergy Immunol; 2005 Mar; 136(3):239-49. PubMed ID: 15722633
    [Abstract] [Full Text] [Related]

  • 9. Differential T-cell responses and allergen uptake after exposure of dendritic cells to the birch pollen allergens Bet v 1.0101, Bet v 1.0401 and Bet v 1.1001.
    Smole U, Balazs N, Hoffmann-Sommergruber K, Radauer C, Hafner C, Wallner M, Ferreira F, Grössinger R, de Jong EC, Wagner S, Breiteneder H.
    Immunobiology; 2010 Nov; 215(11):903-9. PubMed ID: 20005001
    [Abstract] [Full Text] [Related]

  • 10. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1.
    Mahler V, Vrtala S, Kuss O, Diepgen TL, Suck R, Cromwell O, Fiebig H, Hartl A, Thalhamer J, Schuler G, Kraft D, Valenta R.
    Clin Exp Allergy; 2004 Jan; 34(1):115-22. PubMed ID: 14720271
    [Abstract] [Full Text] [Related]

  • 11. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.
    Vrtala S, Akdis CA, Budak F, Akdis M, Blaser K, Kraft D, Valenta R.
    J Immunol; 2000 Dec 01; 165(11):6653-9. PubMed ID: 11086111
    [Abstract] [Full Text] [Related]

  • 12. Skin testing with wild-type recombinant birch pollen allergens and hypoallergenic modified molecules.
    Pauli G, Purohit A, Oster JP, de Blay F, Vrtala S, Niederberger V, Kraft D, Valenta R.
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 1999 Dec 01; (93):203-10. PubMed ID: 11487876
    [Abstract] [Full Text] [Related]

  • 13. Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients.
    Ebner C, Schenk S, Najafian N, Siemann U, Steiner R, Fischer GW, Hoffmann K, Szépfalusi Z, Scheiner O, Kraft D.
    J Immunol; 1995 Feb 15; 154(4):1932-40. PubMed ID: 7530747
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of recombinant allergens Bet v 1 and Bet v 2 (profilin) by Pharmacia CAP system in patients with pollen-related allergy to birch and apple.
    Rossi RE, Monasterolo G, Operti D, Corsi M.
    Allergy; 1996 Dec 15; 51(12):940-5. PubMed ID: 9020425
    [Abstract] [Full Text] [Related]

  • 15. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice.
    Wiedermann U, Herz U, Baier K, Vrtala S, Neuhaus-Steinmetz U, Bohle B, Dekan G, Renz H, Ebner C, Valenta R, Kraft D.
    Int Arch Allergy Immunol; 2001 Sep 15; 126(1):68-77. PubMed ID: 11641608
    [Abstract] [Full Text] [Related]

  • 16. High-level expression and purification of the major birch pollen allergen, Bet v 1.
    Hoffmann-Sommergruber K, Susani M, Ferreira F, Jertschin P, Ahorn H, Steiner R, Kraft D, Scheiner O, Breiteneder H.
    Protein Expr Purif; 1997 Feb 15; 9(1):33-9. PubMed ID: 9116499
    [Abstract] [Full Text] [Related]

  • 17. Characterization of the T cell response to the major hazelnut allergen, Cor a 1.04: evidence for a relevant T cell epitope not cross-reactive with homologous pollen allergens.
    Bohle B, Radakovics A, Lüttkopf D, Jahn-Schmid B, Vieths S, Ebner C.
    Clin Exp Allergy; 2005 Oct 15; 35(10):1392-9. PubMed ID: 16238801
    [Abstract] [Full Text] [Related]

  • 18. Bet v 1, the major birch pollen allergen, initiates sensitization to Api g 1, the major allergen in celery: evidence at the T cell level.
    Bohle B, Radakovics A, Jahn-Schmid B, Hoffmann-Sommergruber K, Fischer GF, Ebner C.
    Eur J Immunol; 2003 Dec 15; 33(12):3303-10. PubMed ID: 14635038
    [Abstract] [Full Text] [Related]

  • 19. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
    Kahlert H, Suck R, Weber B, Nandy A, Wald M, Keller W, Cromwell O, Fiebig H.
    Int Arch Allergy Immunol; 2008 Dec 15; 145(3):193-206. PubMed ID: 17912007
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
    Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R, Purohit A, Arvidsson M, Kavina A, Schroeder JW, Mothes N, Spitzauer S, Montagut A, Galvain S, Melac M, André C, Poulsen LK, Malling HJ.
    J Allergy Clin Immunol; 2008 Nov 15; 122(5):951-60. PubMed ID: 19000581
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.